[go: up one dir, main page]

UA92355C2 - urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS - Google Patents

urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS

Info

Publication number
UA92355C2
UA92355C2 UAA200800924A UAA200800924A UA92355C2 UA 92355 C2 UA92355 C2 UA 92355C2 UA A200800924 A UAA200800924 A UA A200800924A UA A200800924 A UAA200800924 A UA A200800924A UA 92355 C2 UA92355 C2 UA 92355C2
Authority
UA
Ukraine
Prior art keywords
smarttags2
aurorainhibitors
schemas
urn
diamino
Prior art date
Application number
UAA200800924A
Other languages
English (en)
Ukrainian (uk)
Inventor
Штефан Карл Цан
Гвидо Бёмельт
Андреас Мантоулидис
Ульрих Райзер
Маттиас Треу
Ульрих Гуэртлер
Андреас Шооп
Флавио Золька
Ульрике Тонтш-Грунт
Ральф Брюкнер
Шарлотте Райтер
Ларс Херфурт
Оливер Кремер
Хайнц Штадтмюллер
Харальд Энгельхардт
Original Assignee
Бьорингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бьорингер Ингельхайм Интернациональ Гмбх filed Critical Бьорингер Ингельхайм Интернациональ Гмбх
Publication of UA92355C2 publication Critical patent/UA92355C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке описаны соединения общей формулы (1), (1)в которойR-Rявляются такими, как определено в п. 1,которые применимы для лечения заболеваний, которые характеризуются чрезмерной или аномальной пролиферацией клеток, и их применение для приготовления фармацевтической композиции, которая имеет указанные выше характеристики.
UAA200800924A 2005-07-01 2006-06-30 urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS UA92355C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05106007 2005-07-01

Publications (1)

Publication Number Publication Date
UA92355C2 true UA92355C2 (en) 2010-10-25

Family

ID=35431858

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200800924A UA92355C2 (en) 2005-07-01 2006-06-30 urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS

Country Status (30)

Country Link
US (3) US20070032514A1 (ru)
EP (1) EP1902037B1 (ru)
JP (1) JP5179357B2 (ru)
KR (1) KR20080031362A (ru)
CN (1) CN101213179A (ru)
AR (1) AR057423A1 (ru)
AT (1) ATE441639T1 (ru)
AU (1) AU2006264958B2 (ru)
BR (1) BRPI0613096A2 (ru)
CA (1) CA2613664A1 (ru)
CY (1) CY1109644T1 (ru)
DE (1) DE502006004750D1 (ru)
DK (1) DK1902037T3 (ru)
EA (1) EA016358B1 (ru)
EC (1) ECSP078060A (ru)
ES (1) ES2330045T3 (ru)
IL (1) IL188452A (ru)
MX (1) MX2007015992A (ru)
MY (1) MY142496A (ru)
NO (1) NO20076059L (ru)
NZ (1) NZ565475A (ru)
PE (1) PE20070121A1 (ru)
PL (1) PL1902037T3 (ru)
PT (1) PT1902037E (ru)
SI (1) SI1902037T1 (ru)
TW (1) TWI369351B (ru)
UA (1) UA92355C2 (ru)
UY (1) UY29636A1 (ru)
WO (1) WO2007003596A1 (ru)
ZA (1) ZA200709763B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566531A1 (en) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
AR060890A1 (es) * 2006-05-15 2008-07-23 Boehringer Ingelheim Int Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
CN101535276B (zh) 2006-10-23 2013-08-28 赛福伦公司 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物
WO2008077885A2 (en) 2006-12-22 2008-07-03 Boehringer Ingelheim International Gmbh 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer
WO2009122180A1 (en) * 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CN102105150B (zh) 2008-05-21 2014-03-12 阿里亚德医药股份有限公司 用作激酶抑制剂的磷衍生物
CA2734489C (en) 2008-08-20 2016-11-08 Southern Research Institute Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020245A (en) * 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
MX2011002470A (es) * 2008-09-08 2011-04-05 Merck Patent Gmbh Pirimidinas macrociclicas como inhibidores de aurora cinasa.
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
WO2010144468A1 (en) 2009-06-10 2010-12-16 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
US20120107304A1 (en) * 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
PT2576541T (pt) 2010-06-04 2016-07-08 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
RS59106B1 (sr) 2010-11-10 2019-09-30 Genentech Inc Derivati pirazol aminopirimidina kao lrrk2 modulatori
PL2678332T3 (pl) * 2011-02-25 2016-12-30 Pochodne diaminopirymidyny i sposoby ich wytwarzania
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CA2905993C (en) 2013-03-14 2022-12-06 Tolero Pharmaceuticals, Inc. Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
ES2812605T3 (es) 2013-12-20 2021-03-17 Signal Pharm Llc Compuestos de diaminopirimidilo sustituidos, composiciones de los mismos y procedimientos de tratamiento con ellos
GB2538476B (en) 2014-05-08 2019-03-20 Tosoh F Tech Inc 5-(Trifluoromethyl)pyrimidine derivatives and method for producing same
WO2018005356A1 (en) 2016-06-27 2018-01-04 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
CA3096984A1 (en) * 2018-04-05 2019-10-10 Sumitomo Dainippon Pharma Oncology, Inc. Axl kinase inhibitors and use of the same
JP2021530554A (ja) 2018-07-26 2021-11-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 異常なａｃｖｒ１発現を伴う疾患を処置するための方法およびそこで使用するためのａｃｖｒ１阻害剤
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100874791B1 (ko) * 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
US7169836B2 (en) * 2001-06-27 2007-01-30 Polyplastics Co., Ltd Flame-retardant resin composition
JP4460292B2 (ja) * 2001-10-17 2010-05-12 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
AU2003265336B8 (en) * 2002-07-29 2009-04-23 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005063722A1 (en) * 2003-12-19 2005-07-14 Rigel Pharmaceuticals, Inc. Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
CN1976905A (zh) * 2004-03-30 2007-06-06 大正制药株式会社 嘧啶衍生物以及与其应用有关的治疗方法
EA200601796A1 (ru) * 2004-05-14 2007-04-27 Пфайзер Продактс, Инк. Пиримидиновые производные для лечения аномального клеточного роста
CA2566531A1 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
CA2590250A1 (en) * 2004-12-14 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrimidine inhibitors of erk protein kinase and uses therof
EA014551B1 (ru) * 2005-12-21 2010-12-30 Пфайзер Продактс Инк. Пиримидиновые производные для лечения аномального клеточного роста

Also Published As

Publication number Publication date
KR20080031362A (ko) 2008-04-08
CN101213179A (zh) 2008-07-02
EA016358B1 (ru) 2012-04-30
US20110251174A1 (en) 2011-10-13
UY29636A1 (es) 2007-01-31
PL1902037T3 (pl) 2010-02-26
DK1902037T3 (da) 2009-12-21
CY1109644T1 (el) 2014-08-13
PE20070121A1 (es) 2007-03-05
BRPI0613096A2 (pt) 2010-12-21
EP1902037B1 (de) 2009-09-02
EA200800172A1 (ru) 2008-08-29
TWI369351B (en) 2012-08-01
ATE441639T1 (de) 2009-09-15
US20070032514A1 (en) 2007-02-08
MX2007015992A (es) 2008-03-07
JP5179357B2 (ja) 2013-04-10
MY142496A (en) 2010-11-30
AU2006264958B2 (en) 2012-05-03
JP2008544972A (ja) 2008-12-11
ZA200709763B (en) 2008-12-31
TW200726753A (en) 2007-07-16
AR057423A1 (es) 2007-12-05
PT1902037E (pt) 2009-10-13
DE502006004750D1 (de) 2009-10-15
ES2330045T3 (es) 2009-12-03
ECSP078060A (es) 2008-01-23
AU2006264958A1 (en) 2007-01-11
NO20076059L (no) 2008-01-30
WO2007003596A1 (de) 2007-01-11
SI1902037T1 (sl) 2010-01-29
IL188452A0 (en) 2008-04-13
NZ565475A (en) 2010-01-29
US20130281429A1 (en) 2013-10-24
CA2613664A1 (en) 2007-01-11
EP1902037A1 (de) 2008-03-26
IL188452A (en) 2012-02-29

Similar Documents

Publication Publication Date Title
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
UA85559C2 (en) Aminobenzophenone compounds
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
GEP20125565B (en) Lactam compounds and their pharmaceutical use
UA95298C2 (ru) Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
UA94944C2 (ru) 2,4-диаминопиримидины как ингибиторы киназ, которые принимают участие в регуляции клеточного цикла
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
TW200612892A (en) Novel compounds
TW200738659A (en) Novel compounds
TW200630374A (en) Thiazolyldihydroindazoles
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
JO2282B1 (en) Oxazole derivatives
WO2004013120A8 (en) Novel benzodioxoles
TW200732296A (en) Novel compounds
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
MY138708A (en) Biaryloxymethylarenecarboxylic acids
MA32505B1 (fr) 5-alcynyl-pyrimidines
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
NO20082096L (no) Azaindol-2-karboksamidderivativer
TW200700071A (en) Novel use
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
TW200640911A (en) Novel, long acting betamimetics for the treatment of respiratory diseases
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof